These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2185297)

  • 21. Critical appraisal of 13C breath tests for microsomal liver function: aminopyrine revisited.
    Pijls KE; de Vries H; Nikkessen S; Bast A; Wodzig WK; Koek GH
    Liver Int; 2014 Apr; 34(4):487-94. PubMed ID: 24428683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum metabolite/caffeine ratios as a test for liver function.
    Jodynis-Liebert J; Flieger J; Matuszewska A; Juszczyk J
    J Clin Pharmacol; 2004 Apr; 44(4):338-47. PubMed ID: 15051740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prognostic significance of caffeine half-life in saliva in children with chronic liver disease.
    Baker A; Girling A; Worthington D; Ballantine N; Smith S; Tarlow M; Kelly D
    J Pediatr Gastroenterol Nutr; 1995 Feb; 20(2):196-201. PubMed ID: 7714686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics.
    Perera V; Gross AS; Xu H; McLachlan AJ
    J Pharm Pharmacol; 2011 Sep; 63(9):1161-8. PubMed ID: 21827488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Caffeine: a model compound for measuring liver function.
    Renner E; Wietholtz H; Huguenin P; Arnaud MJ; Preisig R
    Hepatology; 1984; 4(1):38-46. PubMed ID: 6420303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antipyrine and caffeine dispositions in clinically normal dogs and dogs with progressive liver disease.
    Boothe DM; Cullen JM; Calvin JA; Jenkins WL; Brown SA; Green RA; Corrier DE
    Am J Vet Res; 1994 Feb; 55(2):254-61. PubMed ID: 8172417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Diagnostic value of the study of caffeine elimination in chronic liver diseases].
    Darnót G; Nemesánszky E; Bariska J
    Orv Hetil; 1995 Apr; 136(18):927-32. PubMed ID: 7739851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of drug metabolism in hepatic disease: comparison of plasma kinetics of oral cyclobarbital and the intravenous aminopyrine breath test.
    Breyer-Pfaff U; Seyfert H; Weber M; Egberts EH
    Eur J Clin Pharmacol; 1984; 26(1):95-101. PubMed ID: 6143671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salivary clearance and urinary metabolic pattern of caffeine in healthy children and in pediatric patients with hepatocellular diseases.
    el-Yazigi A; Shabib S; al-Rawithi S; Yusuf A; Legayada ES; al-Humidan A
    J Clin Pharmacol; 1999 Apr; 39(4):366-72. PubMed ID: 10197295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liver function assessment by drug metabolism.
    Barstow L; Small RE
    Pharmacotherapy; 1990; 10(4):280-8. PubMed ID: 2388874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Saliva and plasma clearance of antipyrine as reflectors of liver function.
    Luoma PV; Sotaniemi EA
    Eur J Drug Metab Pharmacokinet; 1981; 6(4):261-4. PubMed ID: 7333326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of salivary levels to predict clearance of caffeine in patients with cystic fibrosis.
    Bianchetti MG; Kraemer R; Passweg J; Jost J; Preisig R
    J Pediatr Gastroenterol Nutr; 1988; 7(5):688-93. PubMed ID: 3183872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantitative assessment of hepatic function by breath analysis after oral administration of (14C)aminopyrine.
    Hepner GW; Vesell ES
    Ann Intern Med; 1975 Nov; 83(5):632-8. PubMed ID: 1200495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Caffeine clearance study in hepatocellular carcinoma.
    Tangkijvanich P; Wittayalertpanya S; Kusonsolboon T; Thong-Ngam D; Mahachai V
    J Med Assoc Thai; 1999 Mar; 82(3):297-303. PubMed ID: 10410486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians.
    Akinyinka OO; Sowunmi A; Honeywell R; Renwick AG
    Eur J Clin Pharmacol; 2000 May; 56(2):159-65. PubMed ID: 10877011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison between antipyrine and aminopyrine blood clearances.
    Kawasaki S; Imamura H; Kokudo N; Bandai Y; Sanjo K; Idezuki Y
    Hepatogastroenterology; 1992 Aug; 39(4):344-6. PubMed ID: 1427580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of the time course of drugs with inhibitory effects on hepatic metabolic activity using successive salivary caffeine tests.
    Soto J; Alsar MJ; Sacristan JA
    Pharmacotherapy; 1995; 15(6):781-4. PubMed ID: 8602388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of ketoconazole on hepatic oxidative drug metabolism in the rat in vivo and in vitro.
    Meredith CG; Maldonado AL; Speeg KV
    Drug Metab Dispos; 1985; 13(2):156-62. PubMed ID: 2859162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Caffeine test assessment for measuring liver function in critically ill patients.
    Calatayud O; Rodríguez M; Sánchez-Alcaraz A; Ibáñez P
    J Clin Pharm Ther; 1995 Feb; 20(1):23-9. PubMed ID: 7775610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. (99m)Tc-HEPIDA hepatic clearance as a diagnostic tool: usefulness of a single sample plasma and hepatic clearance of (99m)Tc-HEPIDA for assessment of hepatic parenchyma performance.
    Surma MJ; Frieske I; Jencz K; Kuźmierek J
    Nucl Med Rev Cent East Eur; 2006; 9(2):125-31. PubMed ID: 17304475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.